Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia

This study aims to evaluate the safety and efficacy of LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells) in patients with refractory or relapsed acute myeloid leukemia(AML).

Trial Details

NCT ID
NCT07263906
Phase
PHASE1
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Anti-LILRA6 CAR-T cells
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Voluntarily participate in this study and sign the informed consent form.
  • Age range: 18 - 75 years old. Gender is not restricted.
  • Refractory/Recurrent AML: Meeting any one of the following criteria for refractory or recurrent cases is sufficient. 1) Refractory: (1) In the case…
  • Expected survival period ≥ 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →